Companies › J Ints Bio
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JIN-A02 4th generation EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | EGFR Mutant Advanced Non-small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05394831 | JIN-A02 | Phase 1 | EGFR Mutant Advanced Non-small Cell Lung Cancer | Oncology | Sep 2026 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.